Company Quick10K Filing
Bio-En
Price-0.00 EPS-0
Shares77 P/E0
MCap-0 P/FCF0
Net Debt-0 EBIT-0
TEV-0 TEV/EBIT0
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-03-31 Filed 2020-06-04
10-K 2019-12-31 Filed 2020-05-14
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-10-17
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-03-19
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-14
10-K 2017-12-31 Filed 2018-04-16
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-09
10-Q 2017-03-31 Filed 2017-05-15
10-K 2016-12-31 Filed 2017-03-29
10-Q 2016-09-30 Filed 2016-11-15
10-Q 2016-06-30 Filed 2016-08-11
10-Q 2016-03-31 Filed 2016-05-16
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-09
10-Q 2015-06-30 Filed 2015-08-14
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-04-13
10-Q 2014-09-30 Filed 2014-11-19
10-Q 2014-06-30 Filed 2014-08-14
10-Q 2014-03-31 Filed 2014-05-20
10-K 2013-12-31 Filed 2014-02-19
10-Q 2013-09-30 Filed 2013-10-29
10-Q 2013-06-30 Filed 2013-07-25
10-Q 2013-03-31 Filed 2013-05-08
8-K 2020-05-12
8-K 2020-04-14
8-K 2020-03-27
8-K 2019-11-26
8-K 2019-09-22
8-K 2019-08-26
8-K 2018-03-16
8-K 2018-01-08

BENH 10Q Quarterly Report

Part 1 - Financial Information
Item 1. Financial Statements.
Note 1 - Organization
Note 2 - Summary of Significant Accounting Policies
Note 3 - Purchased Intangible Assets, Net
Note 4 - Account Payable - Related Party
Note 5 - Loan From Related Party
Note 6 - Stockholders' Deficit
Note 7 - Income Taxes
Note 8 - Related Party Transactions
Note 9 - Commitments
Note 10 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part II. - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-31.1 v471903_ex31-1.htm
EX-31.2 v471903_ex31-2.htm
EX-32.1 v471903_ex32-1.htm
EX-32.2 v471903_ex32-2.htm

Bio-En Earnings 2017-06-30

Balance SheetIncome StatementCash Flow
26639584037-98321-280679-463037-6453952012201420172020
Assets, Equity
-3157.0-15239.6-27322.2-39404.8-51487.4-63570.02013201520172019
Rev, G Profit, Net Income
23631014178647262-47262-141786-2363102012201420172020
Ops, Inv, Fin

10-Q 1 v471903_10q.htm FORM 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2017

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission File Number: 333-186629

 

Bio-En Holdings Corp.

(Name of registrant as specified in its charter)

 

Delaware 990369776
(State or other jurisdiction of incorporation or
organization)
(I.R.S. Employer Identification No.)

 

56 Main Street

Monsey, New York 10952

(Address of principal executive offices) (Zip Code)

 

(845) 364-7151

(Registrant's telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x    No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x    No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer  
Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company x
  Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨     No x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of August 8, 2017 there were 32,350,003 shares of common stock issued and outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

 2 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements.

 

We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations, including statements about potential acquisition or merger targets; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts.

 

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

 

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

 

 3 

 

 

PART 1 - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

  

BIO-EN HOLDINGS CORP

INTERIM FINANCIAL STATEMENTS

For the three months ended June 30, 2017

(Unaudited)

 

 

 4 

 

 

BIO-EN HOLDINGS CORP

BALANCE SHEETS

(In U.S. Dollars) 

 

 

June 30, 2017

(unaudited)

  

December 31, 2016

audited

 
   $   $ 
ASSETS        
         
Current assets:          
Cash and cash equivalents   1,052    1,136 
Total current assets   1,052    1,136 
           
Purchased intangible assets, net   216,400    226,088 
           
TOTAL ASSETS   217,452    227,224 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable and accrued liabilities   211,683    194,033 
Accounts payable – related party   232,500    187,500 
Loans from related party   96,051    84,153 
Total current liabilities   540,234    465,686 
           
Non-current liabilities:          
Other payable   279,661    279,661 
           
Total liabilities   819,895    745,347 
           
Stockholders' Equity (Deficit)          
Preferred stock; $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding          
Common stock, $0.0001 par value; 250,000,000 shares authorized; 32,350,003 shares issued and outstanding at June 30, 2017 and December 31, 2016   3,235    3,235 
Additional paid-in capital   120,931    120,931 
Accumulated deficit   (726,609)   (642,289)
Total Stockholders’ Equity (Deficit)   (602,443)   (518,123)
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)   217,452    227,224 

 

The accompanying notes are an integral part of these financial statements.

 

 F-1 

 

 

BIO-EN HOLDINGS CORP

STATEMENTS OF OPERATIONS

(in U.S. Dollars)

(Unaudited)

 

  

Three Months

Ended June 30,

  

Six Months

Ended June 30,

 
   2017   2016   2017   2016 
   $   $         
                 
Operating expenses :                    
General and administrative expenses                    
Amortization expense   4,844    4,844    9,688    9,688 
Directors' compensation   22,500    22,500    45,000    45,000 
Filing fees   2,351    2,045    4,942    4,393 
Other costs   42    42    84    84 
Professional fees:-                    
- Accounting   6,000    6,000    12,000    12,000 
- Auditor's fee   2,500    2,000    4,500    4,000 
- Legal fees   3,710    10,500    5,710    21,000 
Secretarial expenses   -    4,347    1,976    4,414 
Total operating expenses   (41,947)   (52,278)   (83,900)   (100,579)
                     
Interest expenses   180    2,723    420    4,973 
                     
Net loss   (42,127)   (55,001)   (84,320)   (105,552)
                     
Net loss per common share - basic and diluted                    
Net loss per share attributable to common stockholders   -    -    -    - 
                     
Weighted-average number of common shares outstanding   32,350,003    32,350,003    32,350,003    32,350,003 

 

The accompanying notes are an integral part of these financial statements.

 

 F-2 

 

 

BIO-EN HOLDINGS CORP

STATEMENT OF CASH FLOWS

(in U.S. Dollars)

(Unaudited)

 

   Six Months Ended June 30, 
   2017   2016 
   $   $ 
Cash Flows from Operating Activities          
           
Net loss   (84,320)   (105,552)
           
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization Expense   9,688    9,688 
           
Changes in operating assets and liabilities          
Accounts payable and accrued liabilities   17,650    38,380 
Accounts payable – related party   45,000    45,000 
           
Net cash used in operating activities   (11,982)   (12,484)
           
Cash Flows from Investing Activities   -    - 
           
Cash Flows from Financing Activities          
Proceeds from loan with related party   11,898    12,400 
Net cash provided by financing activities   11,898    12,400 
           
Decrease in cash and cash equivalents   (84)   (84)
           
Cash and cash equivalents at beginning of the period   1,136    1,304 
           
Cash and cash equivalents at end of the period   1,052    1,220 

 

The accompanying notes are an integral part of these financial statements.

 

 F-3 

 

 

BIO-EN HOLDINGS CORP

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Three Months ended June 30, 2017

(Unaudited)

 

NOTE 1 – ORGANIZATION 

 

Bio-En Holdings Corp (formerly Olivia Inc.) is a Delaware company (the “Company”), incorporated under the laws of the State of Delaware on August 2, 2011. The Company intends to be a world leader of setting the standard for waste to bio-fuel technologies. The Company is planning, designing and executing agreements to build, operate and maintain a bio-mass to energy facility on the Island of Malta.

 

Effective August 21, 2014, the Company filed with the State of Delaware a Certificate of Amendment to its Articles of Incorporation changing the Company’s name from Olivia, Inc. to Bio-En Holdings Corp.

 

On August 21, 2014, Bio-En Corp merged with, and into Bio-En Holdings Corp (formerly Olivia Inc.), with Bio-En Corp being the surviving entity of the merger and changing its name to Bio-En Holdings Corp. This transaction closed on September 10, 2014 and each issued and outstanding share of common stock of Bio En Corp was converted into one share of common stock in Bio-En Holdings Corp.

 

The completion of the Share Exchange/Merger Agreement resulted in a change of control. The Share Exchange was accounted for as a reverse merger and recapitalization, with Bio-En Corp regarded as the accounting acquirer, since Bio En Corp Shareholders collectively beneficially owned approximately 89.6% of the Common Stock immediately after the Exchange.

 

Basis of Presentation

The Company maintains its accounting records on an accrual basis in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). These financial statements are presented in US dollars.

 

Fiscal Year End

The Corporation has adopted a fiscal year end of December 31.

 

Unaudited Interim Financial Statements

The interim financial statements of the Company as of June 30, 2017, and for the periods then ended are unaudited. However, in the opinion of management, the interim financial statements include all adjustments, consisting of only normal recurring adjustments, necessary to present fairly the Company’s financial position as of June 30, 2017, and the results of its operations and its cash flows for the period ended June 30, 2017. These results are not necessarily indicative of the results expected for the calendar year ending December 31, 2017. The accompanying financial statements and notes thereto do not reflect all disclosures required under accounting principles generally accepted in the United States. Refer to the Company’s audited financial statements as of December 31, 2016, filed with the SEC, for additional information, including significant accounting policies.

 

Functional and Reporting Currency

The Company's reporting currency is the U.S. dollar. The Company’s functional currency is the Euro. The functional currency for its energy projects is the Euro because Malta, an EU member state is the primary economic environment in which the Company conducts its operations. Assets and liabilities of the Malta project are translated using the exchange rate on the respective balance sheet dates. Items in the income statement and cash flow statement are translated into U.S. Dollars using the average rates of exchange for the periods involved. The resulting translation adjustments are recorded as a separate component of other comprehensive income/(loss) within stockholders’ equity.

 

Euro (“EUR”) amounts have been translated into U.S. Dollars at the representative rate of exchange on June 30, 2017 (USD 1 = EUR 0.8771).

 

 F-4 

 

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The principal accounting policies are set out below, these policies have been consistently applied to the period presented, unless otherwise stated:

 

Use of Estimates

The preparation of the interim financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts or revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Going concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As at June 30, 2017, the Company has a working capital deficit of $539,182 and a loss from operations of $84,320 and an accumulated deficit of $726,709 and has earned no revenues since inception. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2017.

 

In response to these problems, management intends to raise additional funds through public or private placement offerings.

 

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Risks and Uncertainties

The Company intends to operate in an industry that is subject to rapid change. The Company's operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential of business failure.

 

Business Segments

The Company operates in one segment and therefore segment information is not presented.

 

Cash and cash equivalents

Cash and equivalents include investments with initial maturities of three months or less. The Company maintains its cash balances at credit-worthy financial institutions that are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000.

 

Property, Plant and Equipment, Net

Property and equipment are stated at cost, less accumulated depreciation. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using shorter of useful live of the property or the unit of depletion method.

 

 F-5 

 

 

Intangible Assets

Identifiable intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually, or more frequently if circumstances indicate a possible impairment may exist. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives, generally on a straight-line basis, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

 

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities are carried at amortized cost and represent liabilities for goods and services provided to the Company prior to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the purchase of these goods and services.

 

Research and Development

Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed.

 

Royalty Expense

Royalties are calculated as the greater of 3% of gross revenues or $330,000. Royalties are payable within 30 days after the end of each calendar quarter. The first minimum royalty payment of $330,000 (including of VAT) is due 30 days after the first anniversary following the Company receiving initial project development funding, client contract or initiation of engineering and shall be due annually thereafter. Royalties are expensed in the statements of operation in the period that the related revenues are recognized, in cost of sales.

 

Share Based Payments

The Company recognizes compensation expense for all equity–based payments in accordance with ASC 718 “Share-based payments". Under fair value recognition provisions, the Company recognizes equity–based compensation net of an estimated forfeiture rate and recognizes compensation cost only for those shares expected to vest over the requisite service period of the award.

 

Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for share–based payments granted to non–employees in accordance with ASC 505, “Equity Based Payments to Non–Employees”. The Company determines the fair value of the stock–based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.

 

Earnings per share

The Company computes net loss per share in accordance with ASC 260, "Earnings per Share" ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all potential dilutive common shares, which comprise options granted to employees.

 

Common stock equivalents totaling, 30,000 on June 30, 2017 were not included in the computation of diluted earnings per share on the statement of operations due to the fact that the Company reported a net loss in the second quarter of 2017 and to do so would be anti-dilutive.

 

Income taxes

The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

 F-6 

 

 

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

- Level 1: Quoted prices in active markets for identical instruments;
- Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments);
- Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments).

 

The carrying values for cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued liabilities, and deferred revenue approximate their fair value due to their short maturities.

 

 F-7 

 

 

NOTE 3 – PURCHASED INTANGIBLE ASSETS, NET

 

The following table summarizes purchased intangible assets as of June 30, 2017. Intangible assets include costs of the initial license to use patented technologies in Malta, related to the conversion of cellulose materials into energy producing Ethanol.

 

   June 30, 2017 
  

Gross

Carrying

Amount

  

Accumulated

Amortization

  

Net

Carrying

Amount

  

Weighted

Average

Useful Life

(in Years)

 
   $   $   $     
Finite lived intangible assets                    
License rights   279,916    (63,516)   216,400    14.4 
Total identifiable intangible assets   279,916    (63,516)   216,400      

 

On March 23, 2014, the Company entered into an Exclusive License Agreement in Malta for the acquisition of the rights to patents for the conversion of cellulose material into energy producing Ethanol. The purchase price includes; a partial initial payment of 10% of the common stock of the Company and $330,000 (including 18% VAT) payable in cash.

 

Amortization expense related to the purchased intangible assets was $9,688 during six months ended June 30, 2017.

 

The estimated future amortization expense of purchased intangible assets as of June 30, 2017, is as follows:

 

  

Estimated

Amortization
Expense

 
   $ 
     
Remaining six months of 2017   9,688 
2018   19,376 
2019   19,376 
2020   19,376 
2021   19,376 
Thereafter   129,208 
Total   216,400 

 

 F-8 

 

 

NOTE 4 – ACCOUNT PAYABLE - RELATED PARTY

 

   June 30,   December 30, 
   2017   2016 
   (Unaudited)     
   $   $ 
           
Account payable – related party   232,500    187,500 

 

The above loan is unsecured, bears no interest and has no set terms of repayment. This loan is repayable on demand.

 

NOTE 5 – LOAN FROM RELATED PARTY

 

   June 30,   December 31, 
   2017   2016 
   (Unaudited)     
   $   $ 
           
Loan from related party   96,051    84,153 

 

The above loan is unsecured, bears 1% interest accrued to the loan and has no set terms of repayment. This loan is repayable on demand.

 

NOTE 6 – STOCKHOLDERS’ DEFICIT

 

Merger

On August 21, 2014 the Company entered into a Share Exchange / Merger Agreement, between Bio-En Holdings Corp f/k/a Olivia, Inc. a Delaware corporation, Serena B. Potash (the Principal Shareholder) and Bio-En Corp, a Delaware corporation. On August 21, 2014 (the “Closing Date”) we filed a certificate of merger in the State of Delaware whereby Bio-En Corp merged with Bio-En Holdings Corp, with Bio-En Holdings Corp the surviving entity.

 

In connection with the Share Exchange / Merger Agreement and our Chief Executive Officer and Director, Ms. Potash, the Agreement provided for; the cancellation by Ms. Potash of 6,024,625 shares of the Company’s common stock representing 84% of the then outstanding common stock (all of which shares have been cancelled by the Company and are now included in the Company’s pool of authorized but unissued shares.).

 

In conjunction with the Merger Agreement, all of the issued and outstanding shares of Bio-En Corp at August 21, 2014 were exchanged for 28,980,000 shares of Bio-En Holdings Corp common stock.

 

Common Stock

For the period from January 6, 2014 to March 31, 2014, the Company issued 4,409,196 shares of common stock at $0.0001 per share for $441, for professional services.

 

On March 23, 2014 the Company issued 2,548,853 shares of common stock at $0.0001 per share for $255, as consideration to purchase license rights to develop and use patented intellectual property as described in note 3.

 

For the period between January 6, 2014 and June 30, 2014 the Company issued 23,041,951 shares of common stock to related parties at $0.0001 per share for $2,304 to related parties for services.

 

Additional Paid-in Capital

During 2014, an officer of the Company paid operating expenses on behalf of the Company totaling $133,454, which was treated as contributed capital.

 

Cancellation of Shares

On August 21, 2014, the Company entered into a Share Exchange and Merger Agreement with Bio-En Holdings Corp, a Delaware Corporation. Pursuant to the agreement the principal shareholder of Bio-En Holdings Corp owning an aggregate of 7,894,625 shares of Bio-En Holding Corp common stock, agreed to cancel 6,024,601 of their shares. All cancelled shares of common stock were returned to the Company’s pool of authorized but unissued shares.

 

NOTE 7 – INCOME TAXES

The (benefit)/provision for income taxes for the periods ended June 30, 2017 and December 31, 2016 differ from the amount which would be expected as a result of applying the statutory tax rates to the losses before income taxes due primarily to changes in the valuation allowance to fully reserve net deferred tax assets.

 

 F-9 

 

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income.

 

   June 30,   December 31, 
   2017   2016 
  

(Unaudited)

$

   $ 
Deferred tax assets:          
Pre-tax loss as reported   (726,609)   (642,289)
U.S. statutory tax rate   34%   34%
Expected tax expense (benefit)   247,047    218,378 
Total deferred tax assets   247,047    218,378 
Less: Valuation allowance   (247,047)   (218,378)
Net deferred tax assets   -    - 

 

The Company has provided a valuation allowance against the full amount of the deferred tax asset due to management’s uncertainty about its realization. As of June 30, 2017, the Company had approximately $726,609 in tax loss carryforwards that can be utilized future periods to reduce taxable income, and expire by the year 2037.

 

NOTE 8 – RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating decisions.

 

A related party transaction is considered to be a transfer of resources or obligations between related parties, regardless of whether or not a price is charged.

 

Details of transactions between the Company and related parties are disclosed below:

 

The following entities have been identified as related parties:

 

Ms. Serena Potash - President/Director
Mr. Bruce Minsky - Secretary
Mr. Peter Hurrell - Vice President and greater than 10% stockholder
Mr. Geoffrey McLaren - Director and greater than 10% stockholder
Mr. Joseph Micalle - Director and greater than 10% stockholder
Mr. Mayer Feiler -Greater than 10% stockholder
Applied Bio-Fuels Limited -Greater than 10% stockholder
GeneSyst International Inc. - Common ownership

 

 F-10 

 

 

   June 30,   December 31, 
   2017   2016 
  

(Unaudited)

$

   $ 
The following transactions were carried out with related parties:          
           
Balance sheets:          
Loan from related party   96,051    84,153 
From time to time, the president of the Company provides advances to the Company for its working capital purposes. These advances bear 1% interest accrued to the loan and are due on demand.          
           
Accounts payable - related party   232,500    187,500 
On December 1, 2014, the Company entered into a director service agreement with Serena B. Potash, Chairman of the Board/Director, Geoffrey McLaren, Director and Joseph Micalle, Director. The Company will pay each Director $30,000 per calendar year, payable in equal payments on the first day of each calendar quarter. In lieu of the Directors taking quarterly fee in cash, the Corporation may, at the election of the Directors, pay the Directors in shares of the common stock. The conversion price of each issuance is calculated by the average of the closing prices per share of the Corporations’ common stock on the five consecutive trading days ending on the trading day immediately preceding end of the calendar quarter discounted by 30%.          
           
Income Statement:          
Compensation expense   45,000    90,000 
Directors' compensation expense consists of monthly salary of $2,500 per director.          

 

 F-11 

 

 

NOTE 9 – COMMITMENTS

 

Independent Contractor Consulting Agreement

The Company entered into a Consulting Agreement on March 23, 2014 with GeneSyst International Inc., to provide Technical Support Services in the field of gravity pressure vessel application and related matters.

 

The Company agreed to retain GeneSyst International Inc. to work as its independent contractor for a minimum annual retainer fee of $150,000. Consulting services commence upon the successful raising of $10,000,000 and commencement of construction of a bio-mass to energy facility on the Island of Malta.

 

Payment of 3% royalties on gross revenues

An initial payment of $330,000 (including of VAT) is due 30 days after the first anniversary following the Company receiving initial project development funding, customer contract or initiation of engineering and shall be due annually thereafter. Royalties are calculated as the greater of $330,000 or 3% of gross revenues, annually.

 

NOTE 10 – SUBSEQUENT EVENTS

 

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

 

 F-12 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following is management’s discussion and analysis of the financial condition and results of operations of Bio-En Holdings Corp. (“Bio-En”, the “Company”, “we”, and “our”) for the quarter ended June 30, 2017. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements. The following information should be read in conjunction with the interim financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Report”).

 

Overview

 

The Company was incorporated under the laws of the State of Delaware on August 2, 2011 as Olivia, Inc. On March 27, 2014, the Company filed with the State of Delaware a Certificate of Amendment to the Articles of Incorporation changing the Company’s name from Olivia, Inc. to Bio-En Holdings Corp.

 

On September 10, 2014 (the “Closing Date”), Bio-En Holdings Corp. (the “Company” or “BHC”) closed on a Share Exchange/Merger Agreement, dated August 21, 2014, (the “Merger Agreement”) by and among (i) the Company, (ii) Bio-En Corp., a Delaware corporation, (“Bio-En”), and (iii) Serena B. Potash, an officer and director of BHC and the majority shareholder of BHC. Pursuant to the terms of the Merger Agreement, Bio-En was merged with and into BHC, with BHC to continue as the surviving corporation (the “Surviving Corporation”) in the Merger, and BHC succeeding to and assuming all the rights, assets, liabilities, debts, and obligations of Bio-En (the “Merger”). Although Bio-En Corp.’s fiscal year-end, prior to the Merger, was June 30, the Company’s fiscal year-end remains December 31.

  

In connection with the Merger, BHC entered into a Cancellation Agreement with Ms. Potash (the “Cancellation Agreement”) whereby Ms. Potash, owning an aggregate of 7,894,625 shares of the BHC’s common stock, cancelled 6,024,625 of her BHC shares. 

 

The Company initially intended to be a world leader by setting the standard for waste to bio-fuel technologies. The Company held, and still holds a license agreement for a portfolio of patents including Gravity Pressure Vessels and supporting appurtenances (“Licensed Technology”).

 

The Company planned to design and execute agreements to build, operate and maintain a bio-mass to energy facility on the Island of Malta, utilizing the Licensed Technology (“Facility”). The Facility would combine technologies from the waste management industry and integrate the recycling of waste, control of carbon dioxide and other emissions, with the profitable production of fuel grade Ethanol.

 

The Company has so far not been successful in obtaining the full funding required to establish the Facility. Consequently, the Company is considering additional or alternative ways of commercializing the Licensed Technologies as well as searching/researching for new investments opportunities, as discussed below. 

 

While the Company still finds value in the Licensed Technology, and usage, and the possibilities of identifying and securing alternative locations to build a like-Facility in an alternative location, to maintain the Company’s viability, the Company has not been able to raise the necessary funds, thus we have been forced to reevaluate our business plans. As such, our principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through starting up a new business or a combination with a business. We will not restrict our potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business.

 

 5 

 

 

The analysis of new business opportunities has and will be undertaken by or under the supervision of our officers and directors. We have unrestricted flexibility in seeking, analyzing and participating in potential business opportunities. In our efforts to analyze potential acquisition targets, we will consider the following kinds of factors:

 

  · Potential for growth, indicated by new technology, anticipated market expansion or new products;
  · Competitive position as compared to other firms of similar size and experience within the industry segment as well as within the industry as a whole;
  · Strength and diversity of management, either in place or scheduled for recruitment;
  · Capital requirements and anticipated availability of required funds, to be provided by us or from operations, through the sale of additional securities, through joint ventures or similar arrangements or from other sources;
  · The cost of participation by us as compared to the perceived tangible and intangible values and potentials;
  · The extent to which the business opportunity can be advanced;
  · The accessibility of required management expertise, personnel, raw materials, services, professional assistance and other required items; and
  · Other relevant factors.

 

In applying the foregoing criteria, no one of which will be controlling, we will attempt to analyze all factors and circumstances and make a determination based upon reasonable investigative measures and available data. Potentially available business opportunities may occur in many different industries, and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex. Due to our limited capital available for investigation, we may not discover or adequately evaluate adverse facts about any opportunity the Company may pursue.

 

Limited Operating History

 

There is no historical financial information about us upon which to base an evaluation of our performance. We are a development stage company and have not generated any revenues to date. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources.

 

Results of Operations

 

   Three Months
Ended
June 30, 2017
   Three Months
Ended
June 30, 2016
 
    (Unaudited)   (Unaudited) 
Revenues  $-   $- 
Total operating expenses   41,947    52,278 
Net loss  $42,127   $55,001 

 

 6 

 

 

For the three months ended June 30, 2017 and 2016

 

Revenues

 

We did not generate any revenues during the three months ended June 30, 2017 and 2016.

 

Operating Expenses

 

We incurred total operating expenses of $41,947 and $52,278 for the three months ended June 30, 2017 and 2016, respectively. All of these expenses related to general and administrative expenses.

 

Net Loss

 

During the three months ended June 30, 2017 and 2016, we incurred a net loss of $42,127 and $55,001, respectively, a decrease of $12,874. This decrease was due mainly to a decrease in professional fees. 

 

For the six months ended June 30, 2017 and 2016

 

Revenues

 

We did not generate any revenues during the six months ended June 30, 2017 and 2016.

 

Operating Expenses

 

We incurred total operating expenses of $83,900 and $100,579 for the six months ended June 30, 2017 and 2016, respectively. All of these expenses related to general and administrative expenses.

 

Net Loss

 

During the six months ended June 30, 2017 and 2016, we incurred a net loss of $84,320 and $105,552, respectively, a decrease of $21,232. This decrease was due mainly to a decrease in professional fees.

 

Liquidity and Capital Resources 

 

As at June 30, 2017, the Company has a working capital deficit of $539,182, a net loss of $84,320 and has not earned any revenues to cover its operating costs. The Company intends to fund future operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2017.

 

The ability of the Company to realize its business plan is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

 

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Inflation

 

We do not believe that inflation has had a material effect on our results of operations.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to select appropriate accounting policies and to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts or revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Intangible Assets

 

Identifiable intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually, or more frequently if circumstances indicate a possible impairment may exist. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives, generally on a straight-line basis, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

 

 7 

 

 

Share Based Payments

 

The Company recognizes compensation expense for all equity–based payments in accordance with ASC 718 “Share-based payments". Under fair value recognition provisions, the Company recognizes equity–based compensation net of an estimated forfeiture rate and recognizes compensation cost only for those shares expected to vest over the requisite service period of the award.

 

Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for share–based payments granted to non–employees in accordance with ASC 505, “Equity Based Payments to Non–Employees”. The Company determines the fair value of the stock–based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.

 

Recent Accounting Pronouncements

 

During 2014, the Company elected to early adopt Accounting Standards Update (“ASU”) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to development stage.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 4. Controls and Procedures.

 

Disclosure of Controls and Procedures

 

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934 are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer have reviewed the effectiveness of our disclosure controls and procedures as of June 30, 2017 and, based on his evaluation, and has concluded that the disclosure controls and procedures were not effective due to the material weaknesses, which is that we did not sufficiently segregate duties over incompatible functions at our corporate headquarters.

 

 8 

 

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended June 30, 2017 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II. - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company , threatened against or affecting our company, our common stock, or of our company’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

There were no unregistered sales of the Company’s equity securities during the three months ended June 30, 2017.

 

Item 3. Defaults upon Senior Securities

 

There were no defaults upon senior securities during the quarter ended June 30, 2017. 

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other information

 

There is no other information required to be disclosed under this item which was not previously disclosed. 

 

 9 

 

 

Item 6. Exhibits

 

Exhibits   Description
     
31.1*    Certification of the Principal Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certification of the Principal Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of the Principal Executive Officer of the Registrant pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2*   Certification of the Principal Financial Officer of the Registrant pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS*   XBRL Instance Document
     
101.SCH*   XBRL Taxonomy Schema
     
101.CAL*   XBRL Taxonomy Calculation Linkbase
     
101.DEF*   XBRL Taxonomy Definition Linkbase
     
101.LAB*   XBRL Taxonomy Label Linkbase
     
101.PRE*   XBRL Taxonomy Presentation Linkbase

 

* Filed herewith.

 

 10 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  BIO-EN HOLDINGS CORP.
Date:  August 9, 2017    
  By: /s/ Serena B. Potash
    Serena B. Potash
    President
    (Principal Executive Officer)
     

 

Date: August 9, 2017    
  By: /s/ Ossie Weitzman
    Ossie Weitzman
    Chief Financial Officer 
    (Principal Financial Officer)

 

 

 11